dr richard stone discusses the results of the calgb 10603/ratify study
Published 8 years ago • 156 plays • Length 2:59Download video MP4
Download video MP3
Similar videos
-
2:15
an overview of the calgb 10603 trial in aml
-
4:28
the rationale of flt3 inhibition in aml
-
5:02
richard stone, md: new flt3 inhibitor crenolanib shows promise in flt3-mutated aml
-
1:30
richard stone, md, shares thoughts on current treatment strategies for elderly aml patients
-
2:01
stone: midostaurin for newly diagnosed aml
-
39:50
flt3 inhibitors in the therapy of acute myeloid leukemia
-
5:14
quizartinib in aml
-
1:05
richard stone, md, provides opinion on whether all aml patients should be tested for flt3 mutations
-
1:26
richard stone, md, offers his impression of the landscape for flt3 inhibition in aml
-
3:31
prof. richard stone | ebmt 2018 | latest advances in monitoring mrd in aml
-
6:12
the efficacy of midostaurin in subsets of aml
-
39:50
flt3 inhibitors in the therapy of acute myeloid leukemia
-
2:21
the future of aml treatment? progress in idh1/2 inhibitors for aml
-
4:26
emerging targeted agents in aml
-
44:12
acute myeloid leukemia and the role of flt3 inhibitors: best practices for the interprofessional ...
-
4:47
the use of flt3 inhibitors in aml
-
6:35
what is the emerging role of flt3 inhibitors in the treatment of newly diagnosed aml?
-
0:27
cancer research, best of 2010s: richard stone, md
-
5:20
asp2215 successfully inhibits flt3 in high-risk aml patients